Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5374143 | 0.81 | MEN1 (0.48) | MAPK14MEN1KMT2AGAA | |
| SCHEMBL5733851 | 0.79 | MEN1 (0.50) | MEN1KMT2AGAA | |
| SCHEMBL5205297 | 0.79 | MEN1 (0.52) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL5204083 | 0.76 | CYP2C9 (0.52) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL5369147 | 0.76 | MEN1 (0.49) | MEN1KMT2AGAA | |
| SCHEMBL5374214 | 0.75 | MEN1 (0.49) | MEN1KMT2AGAA | |
| SCHEMBL7220283 | 0.75 | MEN1 (0.48) | MEN1KMT2AGAA | |
| SCHEMBL5375992 | 0.74 | MEN1 (0.53) | MEN1KMT2AGAA | |
| SCHEMBL5377983 | 0.74 | GAA (0.47) | MEN1KMT2AGAA | |
| SCHEMBL5367501 | 0.73 | GAA (0.52) | MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304048-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1178983-B1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070161649-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. | 2007-07-12 | — | — | US | disclosed |
| US-7238712-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7189726-B2 | Benzofuran derivatives as inhibitors of p38-α kinase | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-6867209-B1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6864260-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030195355-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030162970-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2003-08-28 | — | — | US | disclosed |
| US-20030158417-A1 | Benzofuran derivatives as inhibitors of p38-alpha kinase | SCIOS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030144520-A1 | Indole-type derivatives as inhibitors of p38 kinase | MAVUNKEL BABU J (US) | 2003-07-31 | — | — | US | disclosed |
| EP-1178983-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | Scios Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000071535-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161649-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | GRK6, CSNK2A2, CSNK2A1 | CYP2C9 856/4885CYP2C19 1001/4885MAPK14 100/4885 |
| US-20030144520-A1 | Indole-type derivatives as inhibitors of p38 kinase | CNKSR1, MAPK1, CSNK1A1 | CYP2C9 765/4885CYP2C19 744/4885MAPK14 72/4885 |
| US-20030158417-A1 | Benzofuran derivatives as inhibitors of p38-alpha kinase | CNKSR1, CSNK2A1, CSNK1A1 | CYP2C9 1306/4885CYP2C19 1323/4885MAPK14 96/4885 |
| US-20030162970-A1 | Indole-type derivatives as inhibitors of p38 kinase | CNKSR1, MAPK1, CSNK1A1 | CYP2C9 765/4885CYP2C19 744/4885MAPK14 72/4885 |
| US-20030195355-A1 | Indole-type derivatives as inhibitors of p38 kinase | CNKSR1, MAPK1, CSNK1A1 | CYP2C9 765/4885CYP2C19 744/4885MAPK14 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.